Clinical Study Results
Throughout the treatment period, the researchers continued checking the participants’
overall health and tumors.
The table below shows the treatments for each group.
Group 1 Group 2
What treatments • 3 participants got nab-paclitaxel, • 20 participants got durvalumab
were given? gemcitabine, and durvalumab and AZD5069
How were the • Nab-paclitaxel and gemcitabine • Durvalumab was given by IV
treatments were given by IV infusion
given?
• Durvalumab was given by IV
• AZD5069 was taken as a pill
infusion
When were the The participants got nab-paclitaxel and • The participants got durvalumab
treatments gemcitabine: on the 1st day of each cycle
given? • the 1st day of each cycle
• The participants took AZD5069
• the 8th day of each cycle twice a day during each cycle
• the 15th day of each cycle
The participants got durvalumab on the 1st
day of each cycle
After treatment, the study doctors checked the participants’ overall health. They did
this every 4 weeks for 4 months, then every 2 months until the end of the study. The
study doctors also checked the participants’ tumors every 8 weeks in Group 1, or every 6
weeks in Group 2, until their cancer got worse. After 48 weeks, if the participant was still
in the study, tumor checks were only done every 12 weeks.
What were the results of the study?
This is a summary of the main results from this study overall. The results each participant
had might be different and are not in this summary. A full list of the questions researchers
wanted to answer can be found on the websites listed at the end of this summary. If a full
report of the study results is available, it can also be found on these websites.
Researchers look at the results of many studies to decide which treatments work best
and are safest. Other studies may provide new information or different results. Always
talk to a doctor before making any treatment changes.
4